Drugs.com - New Drug Approvals

Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug Administration (FDA) has approved Gemtesa (vibegron), a beta-3 (β3) adrenergic receptor agonist, dosed once-daily...

Feb 9, 2025 - 22:25
 0
Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug Administration (FDA) has approved Gemtesa (vibegron), a beta-3 (β3) adrenergic receptor agonist, dosed once-daily...
Read More

Tags:

Previous Article

Tevimbra Approved in U.S. for First-line Treatment of Gastric and Gastroesophage...

Next Article

FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the Treatment o...

Related Posts

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

FDA Approves Journavx (suzetrigine), a First-in-Class T...

Feb 9, 2025  0

FDA Approves Attruby (acoramidis) to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM

FDA Approves Attruby (acoramidis) to Reduce Cardiovascu...

Feb 9, 2025  0

FDA Approves Miudella (copper intrauterine system) for the Prevention of Pregnancy

FDA Approves Miudella (copper intrauterine system) for ...

Feb 26, 2025  0